US20090054443A1 - Compositions containing riboflavin and sesamin-class compounds - Google Patents
Compositions containing riboflavin and sesamin-class compounds Download PDFInfo
- Publication number
- US20090054443A1 US20090054443A1 US12/282,707 US28270707A US2009054443A1 US 20090054443 A1 US20090054443 A1 US 20090054443A1 US 28270707 A US28270707 A US 28270707A US 2009054443 A1 US2009054443 A1 US 2009054443A1
- Authority
- US
- United States
- Prior art keywords
- sesamin
- riboflavin
- class compound
- fatigue
- class
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 title claims abstract description 246
- 235000019192 riboflavin Nutrition 0.000 title claims abstract description 110
- 239000002151 riboflavin Substances 0.000 title claims abstract description 110
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 title claims abstract description 109
- 229960002477 riboflavin Drugs 0.000 title claims abstract description 109
- 150000001875 compounds Chemical class 0.000 title claims abstract description 106
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 230000002929 anti-fatigue Effects 0.000 claims abstract description 39
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 claims description 54
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 claims description 46
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 claims description 37
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 claims description 18
- 230000001766 physiological effect Effects 0.000 claims description 16
- 229950001574 riboflavin phosphate Drugs 0.000 claims description 16
- 239000000730 antalgic agent Substances 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 9
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 230000000202 analgesic effect Effects 0.000 abstract description 37
- 230000009471 action Effects 0.000 abstract description 35
- 241001465754 Metazoa Species 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 15
- 235000013305 food Nutrition 0.000 abstract description 12
- 235000013361 beverage Nutrition 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 230000037406 food intake Effects 0.000 abstract description 5
- 230000001976 improved effect Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 206010016256 fatigue Diseases 0.000 description 21
- 239000011716 vitamin B2 Substances 0.000 description 21
- 208000002193 Pain Diseases 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 230000036407 pain Effects 0.000 description 17
- 239000004006 olive oil Substances 0.000 description 15
- 235000008390 olive oil Nutrition 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 240000007817 Olea europaea Species 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000008159 sesame oil Substances 0.000 description 6
- 235000011803 sesame oil Nutrition 0.000 description 6
- -1 vitamin B2 phosphate ester Chemical class 0.000 description 6
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 5
- 208000019914 Mental Fatigue Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 238000007654 immersion Methods 0.000 description 5
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000003405 preventing effect Effects 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229940035676 analgesics Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000003287 riboflavins Chemical class 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241000725101 Clea Species 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000010340 Sleep Deprivation Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 125000001452 riboflavin group Chemical group 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 229940013640 flavin mononucleotide Drugs 0.000 description 2
- 239000011768 flavin mononucleotide Substances 0.000 description 2
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 244000309715 mini pig Species 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- XNWFXTOHNKPYMK-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydrocyclopenta[c]dioxole Chemical class C1OOC2CCCC21 XNWFXTOHNKPYMK-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 241000252229 Carassius auratus Species 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001327682 Oncorhynchus mykiss irideus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001282110 Pagrus major Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- ZZMNWJVJUKMZJY-AFHBHXEDSA-N Sesamolin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3OC2=CC=C3OCOC3=C2)=C1 ZZMNWJVJUKMZJY-AFHBHXEDSA-N 0.000 description 1
- ZZMNWJVJUKMZJY-UHFFFAOYSA-N Sesamolin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3OC2=CC=C3OCOC3=C2)=C1 ZZMNWJVJUKMZJY-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000271567 Struthioniformes Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241001504592 Trachurus trachurus Species 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000036997 mental performance Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000030247 mild fever Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- KQRXQIPRDKVZPW-ISZNXKAUSA-N sesaminol Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-ISZNXKAUSA-N 0.000 description 1
- KQRXQIPRDKVZPW-UHFFFAOYSA-N sesaminol Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=3OCOC=3C=C2O)=C1 KQRXQIPRDKVZPW-UHFFFAOYSA-N 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- HELHAJAZNSDZJO-UHFFFAOYSA-L sodium tartrate Chemical compound [Na+].[Na+].[O-]C(=O)C(O)C(O)C([O-])=O HELHAJAZNSDZJO-UHFFFAOYSA-L 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 208000016254 weariness Diseases 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to compositions that can potentiate the physiological activities of riboflavin and which contains both riboflavin and a sesamin-class compound(s); more particularly, the invention relates to compositions having an analgesic action that can prevent and/or reduce the pain due to a variety of diseases and trauma, or to compositions having an anti-fatigue action that can prevent and/or alleviate physical and/or mental fatigue, as well as foods and beverages that contain such compositions.
- Riboflavin also known as vitamin B 2
- vitamin B 2 is a physiologically active substance that is classified as a water-soluble type of vitamins. This riboflavin is said to aid in preventing and treating many eye diseases including cataract, sometimes ameliorating symptoms such as inflammation, drying or itching of the eye, and eye strain (the free encyclopedia Wikipedia; website, http://ja.wikipedia.org/).
- riboflavin-containing compounds have an immunolo-augmenting action (Patent Document 1) and that riboflavin-containing compounds are useful as a toxin shock preventing or treating agent (Patent Document 2).
- Non-patent Document 1 that riboflavin ingested in high doses was effective for migraine prophylaxis was effective for migraine prophylaxis
- Non-patent Document 2 that riboflavin showed an analgesic action against inflammatory pain in a dose-dependent fashion when it was administered intraperitoneally at concentrations of 3 to 100 mg/kg but it was ineffective against pain in the nervous system
- Non-patent Document 2 that when riboflavin was administered perorally at concentrations of 1 to 50 mg/kg, its analgesic effect in a formaldehyde test peaked at 25 mg and did not rise any further even when the dose was increased up to 75 mg
- B vitamins including vitamin B 2 have anti-fatigue actions, namely, the fatigue relieving and preventing actions of B vitamins are known (Patent Document 3).
- supplements and drinks that contain vitamin B 1 , vitamin B 2 and vitamin B 6 are commercially available for ingestion by consumers who are fatigued or have rough skin.
- Non-patent Document 2 European Journal of Pharmacology, 421, 157-164, 2001
- riboflavin As described above, various physiological activities of riboflavin have been reported; however, its effects are not necessarily satisfactory and riboflavin is mainly incorporated for the purpose of supplementing the physiological activities of other compounds and no attempt to enhance the physiological activities of riboflavin per se has been suggested or disclosed.
- B vitamins have been known to have the anti-fatigue action but no specific disclosure has been made about the anti-fatigue action of riboflavin (vitamin B 2 ).
- An object of the present invention is to provide compositions, in particular, foods and beverages, that are safe to humans, animals, etc. and can therefore be ingested for a continued period and which are capable of potentiating the physiological activities of riboflavin.
- the present inventors made intensive studies in order to solve the aforementioned problems and found surprisingly that the physiological activities of riboflavin could be potentiated when ingested together with a sesamin-class compound(s). Specifically, as described above, there is an upper limit to the effect of the analgesic action that can be attained by oral administration of riboflavin alone but the present inventors found that the effect of riboflavin was potentiated by ingesting it together with a sesamin-class compound(s) and that riboflavin displayed an analgesic effect that could not be attained by ingesting it alone.
- the present inventors assessed riboflavin by a swimming behavior test in a water-immersion stress model animal which is regarded as a model for evaluating the degree of fatigue; as a result, they found that riboflavin has an anti-fatigue action. And the present inventors also found that the anti-fatigue action of riboflavin, when combined with a sesamin-class compound(s), was of such a degree that it could not be attained by ingesting riboflavin alone and that riboflavin and a sesamin-class compound(s) displayed an outstanding synergism.
- the present invention relates to the compositions set forth below that include foods and beverages.
- the sesamin-class compound(s) are a concentrate of a sesamin-class compound(s) which contains at least 1 wt % of a sesamin-class compound(s).
- FIG. 1 is a graph showing the effect of sesamin-class compounds on the analgesic action.
- FIG. 2 is a graph showing the analgesic action due to the combination of riboflavin (vitamin B 2 ) and sesamin-class compounds.
- FIG. 3 is a graph showing the synergism in analgesic action due to the combination of riboflavin (vitamin B 2 ) and sesamin-class compounds.
- FIG. 4 is a graph showing the anti-fatigue action due to the combination of riboflavin and sesamin-class compounds.
- FIG. 5 is a graph showing the anti-fatigue action due to the combination of riboflavin and sesamin-class compounds.
- the riboflavin according to the present invention covers riboflavin derivatives or pharmacologically acceptable salts thereof.
- the riboflavin derivatives or pharmacologically acceptable salts thereof specifically include flavin-mononucleotide (FMN), flavin-adenine dinucleotide (FAD), riboflavin tetrabutyrate, riboflavin sodium phosphate (vitamin B 2 phosphate ester), mono- or diethanolamine salt of riboflavin phosphate, riboflavin butyrate (vitamin B 2 butyrate ester), leucoflavin, monohydroflavin, leucoflavin phosphate ester, leucoflavin-mononucleotide, leucoflavin-adenine dinucleotide, etc.
- FMN flavin-mononucleotide
- FAD flavin-adenine dinucleotide
- riboflavin tetrabutyrate
- riboflavin sodium phosphate and highly stable riboflavin butyrate are used with advantage.
- either one or more of the aforementioned riboflavins can be used.
- these are in no way limited in terms of the process for producing them and any products selected from among natural extracts, ferments by microorganisms, and synthetics may be used.
- the sesamin-class compound(s) according to the present invention cover both sesamin and its analogs.
- the sesamin analogs include not only episesamin but they may also include the dioxabicyclo[3.3.0]octane derivative described in JP 4-9331 A.
- a sesamin-class compound(s) may specifically be exemplified by sesamin, sesaminol, episesaminol, sesamolin, and the like; although stereoisomers or racemates of these sesamin-class compounds may be used either alone or in admixture, sesamin and/or episesamin can be used with advantage in the present invention.
- sesamin-class compound(s) such as those described in JP 2001-139579 A
- sesamin analogs covered by the sesamin-class compound(s) according to the present invention can therefore be used in the present invention.
- sesamin-class compound(s) to be used in the present invention are in no way limited by their form, the process for their production, and the like. If, for example, sesamin is chosen as a sesamin-class compounds, sesamin as extracted from sesame oil by a known method (such as the one described in JP 4-9331 A) may commonly be employed (this may be called a sesamin extract or refined sesamin); alternatively, commercially available sesame oil (in liquid form) may be used as such.
- sesame oil in the case where sesame oil is used, its characteristic flavor may occasionally be evaluated as being organoleptically undesirable; therefore, it is preferred to use the sesamin extract (or refined sesamin) that has been extracted from sesame oil and which is tasteless and odorless.
- sesamin extract or refined sesamin
- its sesamin content is so low that when one tries to incorporate a desirable amount of sesamin, the volume of the riboflavin (vitamin B 2 ) containing composition that is prescribed becomes so large per unit dosage that inconveniences in ingestion might occasionally occur.
- the preparation e.g. capsule
- the preparation e.g. capsule
- a sesamin-class compound(s) to be used are preferably a concentrate of a sesamin-class compound(s).
- the degree of concentration may be set as appropriate for the kinds of the sesamin-class compound(s) to be used and the form of the composition into which they are incorporated; it is usually preferred to employ a concentrate of a sesamin-class compound(s) in which the sesamin-class compound(s) are concentrated to at least 1 wt %.
- the content of sesamin-class compound(s) in the concentrate of sesamin-class compound(s) is at least 20 wt %, even more preferably at least 50 wt %, still more preferably at least 70 wt %, and concentrating (refining) up to 90 wt % or more is optimum.
- the sesamin-class compound(s) to be used in the present invention are either compounds found in conventional foods or analog compounds thereof and, obviously, they excel in terms of safety. This is also clear from the fact that when 7-week old ICR male mice were administered (orally administered) sesamin for a continued period of 2 weeks at a dose of 2.14 g/day/kg, no abnormal symptoms were observed.
- sesamin-class compound(s) to be used in the present invention in particular, sesamin and/or episesamin, have an autonomic nervous system modulating action (International Publication WO 2004/105749); however, they were entirely unknown to show the actions claimed by the present invention, i.e., an action that potentiates the analgesic action, as well as an anti-fatigue action, and it has been neither disclosed nor suggested that they can potentiate the physiological activities of riboflavin.
- the present invention is useful as an analgesic agent that prevents and/or reduces the pain in humans and animals, particularly in humans.
- the term “animals” as used herein refers to industrial animals, pets, and laboratory animals; specifically, industrial animals refers to those animals which are required to be kept for industrial purposes, including livestock such as cattle, horses, pigs, goats, sheep, etc., poultry such as chickens, ducks, quails, turkeys, ostriches, etc., and fishes such as yellowtail, young yellowtail, red sea bream, common horse mackerel, carp, rainbow trout, eel, etc.; pets refers to so-called pet animals and companion animals, including dogs, cats, marmots, little birds, hamsters, goldfish, etc.; and laboratory animals refers to those animals which are sacrificed for research in such disciplines as medicine, biology, agronomy, pharmacy, etc. and they include mice, rats, guinea pigs, beagles, miniature pigs,
- the analgesic agent of the present invention is intended to combat a broad spectrum of pains, ranging from a transient and slight pain to a chronic unbearable pain. Pain is usually controlled by using analgesics but their effect is not necessarily adequate; if the pain is chronic pain (ache) associated with arthralgia, neuralgia, lumbago, etc., the pain relieving effect of analgesics is just temporary and, what is more, a continued administration of them may often cause side effects such as gastrointestinal disorders, renal disorders, hepatic disorders, etc. In addition, since the pain associated with arthralgia, neuralgia, lumbago, etc. tends to increase with aging, the recent rapid growth of the population of elderly people is increasing social demands for not only mitigating and eliminating pain but also preventing it.
- the analgesic agent of the present invention is useful in combating the above-mentioned various kinds of pains and the diseases that involve such pains.
- the analgesic agent of the present invention which uses a sesamin-class compound(s) in combination with riboflavin, synergistically potentiates the analgesic action of riboflavin, thereby displaying a superior analgesic action than conventional analgesics.
- its active ingredients are riboflavin and a sesamin-class compound(s) which have been ingested for many years in the form of foods or beverages, so it has no side effects and can be ingested for a continued period.
- analgesic agent which is not only suitable for regular ingestion in order to reduce chronic pain but which can also prevent disease that involves pain (e.g., dysmenorrhea).
- This may qualify the analgesic agent of the present invention as a useful drug in view of the circumstances under which the sense of pain differs between a highly sensitive person and a less sensitive person and in the absence of an objective scale, it is often difficult to make a clear distinction between a normal state and a diseased state, and it has been desired that the conventional therapeutic act which involves administering medications such as analgesics should be replaced by foods and beverages in forms that can be ingested regularly.
- composition of the present invention in addition to exhibiting the above-described analgesic action, is useful as an anti-fatigue agent in humans and animals.
- mammals refers to those animals to which the above-described analgesic agent is to be applied and, in particular, the anti-fatigue agent of the present invention is used in industrial animals, pets, and laboratory animals that perceive pain and it is used in humans with particular advantage.
- industrial animals refers to livestock such as cattle, horses, pigs, goats, sheep, etc., as well as racing horses, hunting dogs, etc.; pets refers to dogs, cats, etc.; and laboratory animals refers to those animals which are sacrificed for research in such disciplines as medicine, biology, agronomy, pharmacy, etc. and they include mice, rats, guinea pigs, beagles, miniature pigs, rhesus monkeys, crab-eating monkeys, etc.
- Fatigue is a temporary decrease in both physical and mental performances that is observed when a physical and a mental stress is applied continuously and the decreased performance means a qualitative or quantitative drop in the capacity for physical and metal work.
- the term “fatigue” as used in the present invention shall cover chronic fatigue syndrome and death from overwork.
- the anti-fatigue agent of the present invention has the action of attenuating the above-defined fatigue or restoring from such fatigue; specific examples include the actions of prolonging the time of duration for which an exercising or operating site (including the brain) works, and suppressing the increase of a fatigue-inducing substance in response to the same amount of exercise or operation (improving endurance or enhancing physical strength) and improving such a condition that the brain or nerves are in a state of sensing fatigue although an exercising or operating site has not been fatigued, as well as promoting the recovery from the fatigued state of an exercising or operating site to the normal state.
- the chronic fatigue syndrome to be combated by the anti-fatigue agent of the present invention means fundamental symptoms such as a feeling of systemic fatigue, a feeling of weariness, mild fever, swollen lymph nodes, muscular pain, arthralgia, psychoneurotic symptoms, etc. that last for such a prolonged period as to cause impediments in daily life.
- the anti-fatigue agent of the present invention can treat this chronic fatigue syndrome, namely, palliate the respective symptoms of chronic fatigue syndrome and bring them into the normal state.
- the death from overwork which is to be combated by the anti-fatigue agent of the present invention means such a condition that although the subject is in a seriously strained state and unable to maintain the physical vigor, the subject is no longer capable of reasonably sensing the fatigue and consequently manifests a cardiovascular disease or cardiac disease to result in permanent disability to work or even death.
- the anti-fatigue agent of the present invention can treat chronic fatigue syndrome and can thereby prevent death from overwork.
- the anti-fatigue effect according to the present invention may typically be confirmed by the following test. That is, by measuring the swimming time in a water-immersion sleep deprivation test. A mouse, kept in such an environment as water immersion that they are unable to have a sufficient sleep or resting position to rest physically or mentally, is forced to swim under the stress of a weight and the time it takes to have its nose submerged in the water for at least 10 seconds is measured to determine the degree of its fatigue.
- this animal model is a physical and mental fatigue model, if the administration of a test substance prolongs the swimming time, it is confirmed that the model has resistance to fatigue, as exemplified by prevention or amelioration of physical and mental fatigue and the accompanying distress such as muscular pain, an increase in physical strength that helps prolong the time to exhaustion, and maintenance of physical vigor in a fatigued state.
- the anti-fatigue agent of the present invention if ingested by humans or animals, makes them less fatigable, and it is also effective in relieving fatigue (recovery from fatigue). Stated more specifically, if physical fatigue is felt during muscular exercise such as sports or if mental fatigue is felt during a continuous operation such as accounting work, the anti-fatigue agent of the present invention may of course be ingested to relieve the fatigue. What is more, if it is ingested in advance before working or playing sports, prevention of fatigue can also be realized. In addition, if it is ingested before or during playing sports, an improvement of endurance is expected. Furthermore, if it is ingested regularly, mental fatigue and the accompanying disease can also be prevented. (Composition containing riboflavin and a sesamin-class compound(s))
- a sesamin-class compound(s) are contained in riboflavin, thereby synergistically potentiating the physiological activities of riboflavin, such as analgesic and anti-fatigue actions; at the same time, if the combination is utilized as health food, the physiological actions of the respective components combine to contribute to health promotion.
- the amounts in which the respective components can be incorporated are not limited if their physiological actions are to be obtained individually.
- riboflavin is preferably incorporated in the amount recommended in the Nutritional Requirements of Japanese People as specified by the Ministry of Health, Labor and Welfare; specifically, it is 1.2 mg for adult male and 1.0 mg for adult female per day.
- a sesamin-class compound(s) they are usually incorporated in such amounts that they range from about 1 to about 200 mg, preferably from about 5 to about 100 mg, for adult per day.
- a sesamin-class compound(s) are incorporated in riboflavin with a view to potentiating its physiological activities, they are incorporated in such amounts that the proportion of the total quantity of a sesamin-class compound(s) to the total quantity of riboflavin taken as unity, when it is calculated as riboflavin (which is hereinafter designated as “riboflavin equivalent”), is no more than 4.5, preferably no more than 4.0, and more preferably no more than 3.5, in weight ratio.
- the lower limit of the amounts of a sesamin-class compound(s) to be incorporated is in no way specified if they are capable of providing the synergism in the desired action such as an analgesic or anti-fatigue action, and they may be incorporated with reference made to the daily doses listed above.
- the proportion of the total quantity of a sesamin-class compound(s) to the total quantity of riboflavin which, when calculated as riboflavin, is taken as unity is at least 0.01, preferably at least 0.5, more preferably at least 0.1, and even more preferably at least 1, in weight ratio.
- riboflavin sodium phosphate is analgesic action and it was confirmed that when 30 mg of riboflavin sodium phosphate in terms of riboflavin equivalent and 50 or 100 mg of a sesamin-class compound(s) were administered perorally, namely, at a riboflavin to sesamins weight ratio of 1:1.67 or 1:3.33, the analgesic action of riboflavin sodium phosphate was improved (Examples 1 and 2).
- the present inventors also confirmed that another physiological activity of riboflavin is anti-fatigue action and it was confirmed that when 25 mg or 50 mg of riboflavin sodium phosphate in terms of riboflavin equivalent and 50 mg of a sesamin-class compound(s) were administered perorally, namely, at a riboflavin to sesamins weight ratio of 1:2 or 1:1, the anti-fatigue action of riboflavin sodium phosphate was improved but that when 10 mg of riboflavin sodium phosphate in terms of riboflavin equivalent and 50 mg of a sesamin-class compound(s) were administered perorally, namely, at a riboflavin to sesamins weight ratio of 1:5, the anti-fatigue action of riboflavin sodium phosphate was not potentiated (Examples 3 and 4).
- composition of the present invention When the composition of the present invention is to be utilized as a pharmaceutical composition, it may be administered perorally in such forms as liquid, tablet, granule, powder, capsule, dry syrup, pill and the like, or it may be administered in the form of an injection or the like; the form of its administration can be selected as appropriate for the clinical condition, the state of its progress, and other conditions.
- riboflavin except riboflavin butyrate
- a sesamin-class compound(s) as the other active ingredient are fat-soluble, so these two ingredients may be ingested in different forms.
- the analgesic action can be obtained by a method in which granules of riboflavin are ingested together with water and, at the same time, soft capsules filled with a sesamin-class compound(s) as they are dissolved in fat or oil are ingested, or by a method in which the granules of riboflavin and the soft capsules of a sesamin-class compound(s) are ingested at different times in accordance with the respective rates of absorption.
- the dose at which the composition of the present invention is administered may also be selected as appropriate for the subject to which it is applied, the clinical condition, the state of its progress, and other conditions such as the form of administration; if it is to be applied perorally to humans (adults) with a view to obtaining the analgesic action and/or the anti-fatigue action, it is generally administered for a continued period at a frequency of about one to three times a day in amounts ranging from about 1 to about 200 mg, preferably from about 2 to about 100 mg.
- any desired ingredients may be incorporated in addition to riboflavin and a sesamin-class compound(s).
- physiologically active components including vitamins such as vitamin E and vitamin C, minerals, hormones, nutritional ingredients, and flavoring agents, but also emulsifiers, isotonization agents, buffers, solvent promoters, preservatives, stabilizers, antioxidants and the like that are incorporated in the pharmaceutical formulating procedure may be incorporated as appropriate.
- the composition of the present invention can be utilized as an analgesic agent and/or an anti-fatigue agent; in addition, since it is believed that various other physiological actions of riboflavin (vitamin B 2 ) and a sesamin-class compound(s) can be exhibited either additively or synergistically, the composition of the present invention can advantageously be utilized not only as the aforementioned pharmaceutical composition but also as health food.
- Examples of the health food as used herein include pharmaceutical preparations or foods, such as capsules or tablets, that contain as an active ingredient the composition of the present invention itself which contains riboflavin and a sesamin-class compound(s), as well as functional foods (including foods for specified health use—FOSHU—and qualified FOSHU) that comprise common foods in which the above-mentioned composition of the present invention is incorporated as one component so that various functions such as analgesic and anti-fatigue actions on the living body are imparted to those foods.
- pharmaceutical preparations or foods such as capsules or tablets, that contain as an active ingredient the composition of the present invention itself which contains riboflavin and a sesamin-class compound(s), as well as functional foods (including foods for specified health use—FOSHU—and qualified FOSHU) that comprise common foods in which the above-mentioned composition of the present invention is incorporated as one component so that various functions such as analgesic and anti-fatigue actions on the living body are imparted to those foods.
- health foods are those which are characterized by having the analgesic action and/or anti-fatigue action and which have labels attached thereto that state they are used for preventing or reducing the pain in the living body or that they mitigate the fatigue of the living body or promote its recovery from fatigue.
- the health foods that contain riboflavin and a sesamin-class compound(s) are not particularly limited in their form and they can be prepared in any form like a solid form such as powder, granules or tablets, or a liquid form such as solution, emulsion or dispersion, or a semi-solid form such paste.
- a test on analgesic action was conducted by a partly modified version of the acetic acid writhing test of Moon et al. (Biol. Pharm. Bull. (2005)).
- the specific test method was as follows. Wistar male rats (5-week old) were purchased from CLEA Japan, Inc. and acclimatized in the test environment for a week; thereafter, the animals that showed normal growth were subjected to the test.
- administration was similarly performed two days before the test and on the day before the test, two administrations were effected, one in the morning and the other in the evening; thus, a total of four administrations were effected.
- rats that had been fasted overnight from the previous night were orally administered with 5 ml/kg of physiological saline and one hour later, they were administered intraperitoneally with 1 ml/170 g of physiological saline containing 1% acetic acid and immediately after this administration, the number of writhing movements the animals made for 30 minutes right after the administration was counted.
- the results are shown in FIG. 1 .
- the groups administered with sesamin-class compounds (Sesamin 50 mg, and Sesamin 100 mg) had a tendency to writhe slightly more often than the control group (Olive), making it clear that sesamin-class compounds had no analgesic action in the acetic acid writhing test.
- a sesamin-class compound(s) were tested for their ability to improve the analgesic action of riboflavin (vitamin B 2 ).
- Wistar male rats (7-week old) were purchased from CLEA Japan, Inc. and acclimatized in the test environment for a week; thereafter, the animals that showed normal growth were subjected to the test.
- the rats were divided into four groups each consisting of 6 heads; two groups of them were orally administered through a tube with olive oil at a dose of 5 ml/kg whereas the remaining two groups were administered with the same sesamin-class compounds as used in Test Example 1 as they were dissolved in olive oil (5 ml/kg) at respective doses of 50 mg/kg and 100 mg/kg; as in Test Example 1, a total of four administrations were effected.
- rats in the control group that had been fasted overnight from the previous night were orally administered with 5 ml/kg of physiological saline whereas similarly fasted rats in the remaining three groups were orally administered with vitamin B 2 (riboflavin sodium phosphate; Nakalai Tesque, Inc.) that was dissolved in physiological saline to give a dose of 30 mg/kg in terms of riboflavin equivalent; then, the number of writhing movements was counted as in Test Example 1.
- vitamin B 2 riboflavin sodium phosphate
- the results are shown in FIG. 2 .
- the sole vitamin B 2 group (Olive+VB2) showed a tendency to make a smaller number of writhing movements than the control group (Olive+Saline), verifying the analgesic action due to vitamin B 2 .
- the groups of sesamin-class compounds and vitamin B 2 in combination (Sesamin 50 mg+VB2, Sesamin 100 mg+VB2) made smaller numbers of writhing movements at the respective sesamins concentrations of 100 mg/kg and 50 mg/kg. It became clear that the analgesic action of vitamin B 2 was potentiated by combining it with a sesamin-class compound(s).
- Example 1 was checked for its reproducibility. Wistar male rats (7-week old) were purchased from CLEA Japan, Inc. and acclimatized in the test environment for a week; thereafter, the animals that showed normal growth were subjected to the test. Three days before the acetic acid writhing test, the rats were divided into three groups each consisting of 10-18 heads; two groups of them (groups 1 and 2) were orally administered through a tube with olive oil at a dose of 5 ml/kg whereas the remaining two groups (groups 3 and 4) were administered with the same sesamin-class compounds as used in Example 1 as they were dissolved in olive oil (5 ml/kg) at a dose of 100 mg/kg; as in Example 1, a total of four administrations were effected.
- rats in two of the four groups that had been fasted overnight from the previous night were orally administered with 5 ml/kg of physiological saline whereas similarly fasted rats in the remaining two groups (groups 2 and 4) were orally administered with vitamin B 2 (riboflavin sodium phosphate; Nakalai Tesque, Inc.) that was dissolved in physiological saline to give a dose of 30 mg/kg in terms of riboflavin equivalent; then, the number of writhing movements was counted as in Test Example 1.
- vitamin B 2 riboflavin sodium phosphate
- the group of vitamin B 2 and sesamin-class compounds in combination (Sesamin+VB2) experienced a considerable decrease in the number of writhing movements (26.6% suppression) and the synergistic analgesic effect due to vitamin B 2 and a sesamin-class compound(s) could be confirmed (according to the result of a Tukey multiple comparison test, the risk was p ⁇ 0.05 between the group of vitamin B 2 and sesamin-class compounds in combination and the control group, and p ⁇ 0.01 between the group of vitamin B 2 and sesamin-class compounds in combination and the sole sesamin-class compounds group).
- the effect against fatigue was evaluated by a water immersion sleep deprivation test. Evaluation was performed by a partially modified version of the method of Tanaka et al. (Neuroscience Let. 352, 159-162, 2003). To be more specific, eight-week old male Balb/b mice were used as test animals and divided into seven groups as shown in Table 1, each consisting of 9 heads and having the same average body weight. The values of riboflavin given in Table 1 were obtained by calculating as riboflavin the riboflavin sodium phosphate used. Of the seven groups of rats, six were water-immersed, sleep-deprived stress groups, which were kept in cages with floor coverings being replaced by 23° C.
- the respective test samples were forcibly administered through the mouth for 2 days on a once-a-day basis.
- the sesamin-class compounds were dissolved in olive oil and the riboflavin in distilled water.
- the order of administration was such that riboflavin was followed by sesamin-class compounds, and the control group was forcibly administered with distilled water and olive oil through the mouth.
- mice After two days of water immersion, the mice were allowed to swim with a weight attached to each of their tails having a mass equivalent to 8% of their body weight and the time they took to have their nose submerged in water for at least 10 seconds was measured.
- the mice of the water-immersed group (the water-immersed, sleep deprived stress group) could swim for a shorter period than the mice of the normally kept group and the effect of the test samples against fatigue was determined by seeing how much the shortening of the swimming time could be suppressed in the mice of the test sample administered groups.
- the anti-fatigue action due to riboflavin and a sesamin-class compound(s) was measured as in Example 3, except that the mice were divided into six groups as shown in Table 2.
- the values of riboflavin given in Table 2 were obtained by calculating as riboflavin the riboflavin sodium phosphate used.
- the particles of these ingredients were mixed uniformly and 100 ml of a solution having 10% hydroxypropyl cellulose dissolved in ethanol was added, followed by blending, extruding and drying in the usual manner to prepare granules.
- composition comprising the ingredients shown below was filled to prepare soft capsules each weighing 200 mg.
- the prepared drink would be drunk in a volume of about 100 ml at one time.
- composition of the present invention which contains riboflavin and a sesamin-class compound(s) has the advantage that the physiological activities of riboflavin, for example, analgesic and anti-fatigue actions, are synergistically displayed by ingesting riboflavin in combination with a sesamin-class compound(s); the composition is safe to humans, animals, etc. and can therefore be ingested for a continued period.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006070487 | 2006-03-15 | ||
JP2006-070487 | 2006-03-15 | ||
PCT/JP2007/055270 WO2007119378A1 (ja) | 2006-03-15 | 2007-03-15 | リボフラビンとセサミン類とを含有する組成物 |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/055270 A-371-Of-International WO2007119378A1 (ja) | 2006-03-15 | 2007-03-15 | リボフラビンとセサミン類とを含有する組成物 |
JPPCT/JP2007/005270 A-371-Of-International | 2007-03-15 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/551,188 Division US9895375B2 (en) | 2006-03-15 | 2014-11-24 | Compositions containing riboflavin and sesamin-class compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090054443A1 true US20090054443A1 (en) | 2009-02-26 |
Family
ID=38609174
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/282,707 Abandoned US20090054443A1 (en) | 2006-03-15 | 2007-03-15 | Compositions containing riboflavin and sesamin-class compounds |
US14/551,188 Active US9895375B2 (en) | 2006-03-15 | 2014-11-24 | Compositions containing riboflavin and sesamin-class compounds |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/551,188 Active US9895375B2 (en) | 2006-03-15 | 2014-11-24 | Compositions containing riboflavin and sesamin-class compounds |
Country Status (12)
Country | Link |
---|---|
US (2) | US20090054443A1 (de) |
EP (2) | EP2826481A1 (de) |
JP (2) | JP5430927B2 (de) |
KR (1) | KR101451438B1 (de) |
CN (1) | CN101410115B (de) |
AU (1) | AU2007237685B2 (de) |
CA (1) | CA2645833C (de) |
HK (2) | HK1126663A1 (de) |
MY (1) | MY163134A (de) |
SG (1) | SG170120A1 (de) |
TW (1) | TWI407963B (de) |
WO (1) | WO2007119378A1 (de) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100048695A1 (en) * | 2007-03-15 | 2010-02-25 | Yoshiko Ono | Anti-fatigue agent |
US20100184793A1 (en) * | 2007-09-19 | 2010-07-22 | Suntory Holdings Limited | Compositions incorporating sesamin-class compounds and vitamin b1 class compounds |
US20100261785A1 (en) * | 2007-09-19 | 2010-10-14 | Suntory Holdings Limited | Compositions containing sesamin-class compound(s) and arachidonic acid class compound(s) |
US9895375B2 (en) | 2006-03-15 | 2018-02-20 | Suntory Holdings Limited | Compositions containing riboflavin and sesamin-class compounds |
US20210283165A1 (en) * | 2021-03-11 | 2021-09-16 | Nidal Toman | Constituent combination for treating stress |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5069416B2 (ja) * | 2006-03-15 | 2012-11-07 | サントリーホールディングス株式会社 | 吸湿性の改善された飲食品用組成物 |
WO2009038089A1 (ja) * | 2007-09-19 | 2009-03-26 | Suntory Holdings Limited | セサミン類及びビタミンeを含有する抗疲労剤 |
CN103446197B (zh) * | 2013-09-11 | 2016-04-13 | 白心亮 | 一种保肝制品 |
CN107405329B (zh) * | 2015-03-23 | 2021-04-09 | 三得利控股株式会社 | 昼夜节律改善用组合物 |
JP6749665B1 (ja) * | 2019-07-18 | 2020-09-02 | 株式会社東洋新薬 | 経口組成物 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5180588A (en) * | 1989-07-21 | 1993-01-19 | Suntory Limited | Liver function improver |
US5211953A (en) * | 1989-07-21 | 1993-05-18 | Suntory, Limited | Liver function improver |
US5637610A (en) * | 1991-06-15 | 1997-06-10 | Suntory Limited | Composition containing dioxabicyclo [3.3.0] octane derivative |
US5814632A (en) * | 1991-09-13 | 1998-09-29 | Eisai Co., Ltd. | Immunopotentiating and infection protective agent and production thereof |
US20040059110A1 (en) * | 2001-02-02 | 2004-03-25 | Ajinomoto Co., Inc. | Novel cystine derivative and agent for suppressing activation of inflammatory factors |
US20050158424A1 (en) * | 2002-04-11 | 2005-07-21 | Yuichiro Nakano | Liquid food/drink containing fat-soluble vitamin and method of stabilizing fat-soluble vitamin |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4427694A (en) | 1982-06-11 | 1984-01-24 | The Vinoxen Company, Inc. | Sesamin as a psychotropic agent |
JP3001589B2 (ja) * | 1989-07-21 | 2000-01-24 | サントリー株式会社 | リグナン類含有飲食物 |
JP3075358B2 (ja) | 1990-04-03 | 2000-08-14 | サントリー株式会社 | 肝機能改善剤 |
JPH04278067A (ja) | 1991-03-05 | 1992-10-02 | Suntory Ltd | 胡麻入り飲料 |
GB9116054D0 (en) | 1991-07-24 | 1991-09-11 | Efamol Holdings | Preparation of fatty acid medicaments |
JPH0551388A (ja) | 1991-08-23 | 1993-03-02 | Suntory Ltd | 過酸化脂質生成抑制剤 |
JPH0558902A (ja) | 1991-08-30 | 1993-03-09 | Nippon Oil & Fats Co Ltd | アレルギー予防油脂組成物 |
JP3636207B2 (ja) | 1991-09-13 | 2005-04-06 | エーザイ株式会社 | 免疫賦活・感染防御剤及びその製造方法 |
AU664602B2 (en) * | 1992-02-17 | 1995-11-23 | Manabu Nomura | Hair growth and restoration promoter |
JPH06327435A (ja) | 1992-11-10 | 1994-11-29 | Otsuka Pharmaceut Co Ltd | 栄養補給組成物 |
JPH06227977A (ja) | 1993-02-01 | 1994-08-16 | Suntory Ltd | 活性酸素消去剤 |
JP2677949B2 (ja) | 1993-08-26 | 1997-11-17 | 常盤薬品工業株式会社 | アラキドン酸含有健康食品 |
JPH0826987A (ja) | 1994-05-12 | 1996-01-30 | Hirohiko Kuratsune | アシルカルニチン含有製剤 |
JPH0847381A (ja) | 1994-08-08 | 1996-02-20 | Meiji Seika Kaisha Ltd | 持久力向上飲食品 |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
EP0782827B1 (de) | 1995-07-04 | 2003-10-01 | Suntory Limited | Verwendung eines ausgleichenden zusatzstoffes für omega-6 und omega-3 ungesättigte fettsäure |
JP4526047B2 (ja) | 1995-11-08 | 2010-08-18 | 雪印乳業株式会社 | 体力増強剤 |
US5993795A (en) | 1995-11-09 | 1999-11-30 | Takemoto Yushi Kabushiki Kaisha | Protein composition derived from sesame seed and use thereof |
JP3286831B2 (ja) | 1996-04-01 | 2002-05-27 | エーザイ株式会社 | ビタミンb2含有医薬 |
JPH10218785A (ja) | 1997-02-12 | 1998-08-18 | Misaki Takemura | 滋養強壮剤 |
US6172106B1 (en) * | 1998-02-09 | 2001-01-09 | R. Armour Forse | Sesamol inhibition of Δ-5-desaturase activity and uses therefor |
DK0951842T3 (da) * | 1999-01-20 | 2003-01-06 | Nutricia Nv | Ernæringsprodukt til et spædbarn |
JP2001046021A (ja) | 1999-08-10 | 2001-02-20 | Itoham Foods Inc | 体力増強・疲労回復用素材及びそれを用いた食品 |
KR20010029185A (ko) * | 1999-09-29 | 2001-04-06 | 손남율 | 항바이러스제 및 항암제 |
JP3789699B2 (ja) | 1999-11-18 | 2006-06-28 | サントリー株式会社 | リグナン系抗酸化剤及びその製造法 |
AU2001296014A1 (en) | 2000-10-27 | 2002-05-06 | Meiji Dairies Corporation | Agents for recoverying from or preventing fatigue in the central nerve system and foods for recoverying from or preventing fatigue |
KR20020090077A (ko) | 2001-05-23 | 2002-11-30 | 정성일 | 노화예방, 정력보강, 간과 신을돕고 허손을 보호,근력튼튼, 안색이 아름답고 흰머리예방 |
JP2003146844A (ja) * | 2001-11-13 | 2003-05-21 | Ichimaru Pharcos Co Ltd | 毛髪用化粧料組成物 |
US20030105104A1 (en) * | 2001-11-27 | 2003-06-05 | Burzynski Stanislaw R. | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy |
JP2003183172A (ja) * | 2001-12-18 | 2003-07-03 | Takemoto Oil & Fat Co Ltd | 片頭痛の抑制乃至予防治療用経口投与剤 |
US7396554B2 (en) * | 2002-08-16 | 2008-07-08 | Council Of Scientific & Industrial Research | Antioxidant sesame extract |
JP2004189619A (ja) * | 2002-12-09 | 2004-07-08 | Dai Ichi Seiyaku Co Ltd | 滋養強壮剤 |
JP2004345988A (ja) * | 2003-05-21 | 2004-12-09 | Eisai Co Ltd | リボフラビン系化合物を含む医薬組成物 |
JPWO2004105749A1 (ja) | 2003-05-27 | 2006-07-20 | サントリー株式会社 | 自律神経調節作用を有する組成物およびその使用方法 |
US20060121158A1 (en) * | 2003-06-04 | 2006-06-08 | Mario Ferruzzi | Weight management beverage |
JP2005023008A (ja) * | 2003-07-01 | 2005-01-27 | Sankyo Co Ltd | ビタミンb群を含有する内服液剤組成物 |
TWI365716B (en) | 2003-12-02 | 2012-06-11 | Suntory Holdings Ltd | Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same |
US20060115556A1 (en) | 2004-12-01 | 2006-06-01 | Foulger Sidney W | Nutritional supplement drink containing xanthone extracts |
WO2007004570A1 (ja) | 2005-06-30 | 2007-01-11 | Suntory Limited | 持久力向上および/または抗疲労作用を有する組成物 |
JP2007008878A (ja) | 2005-06-30 | 2007-01-18 | Sato Pharmaceutical Co Ltd | 非運動性及び非急性ストレス性疲労の治療剤 |
WO2007043656A1 (ja) | 2005-10-14 | 2007-04-19 | Meiji Pharmaceutical Co., Ltd. | 機能性咀嚼物及びその製造方法並びにその使用方法 |
KR101451438B1 (ko) | 2006-03-15 | 2014-10-15 | 산토리 홀딩스 가부시키가이샤 | 리보플라빈과 세사민류를 함유하는 조성물 |
JP5069416B2 (ja) | 2006-03-15 | 2012-11-07 | サントリーホールディングス株式会社 | 吸湿性の改善された飲食品用組成物 |
CN1836555A (zh) | 2006-04-26 | 2006-09-27 | 金龙德 | 一种携带食用方便的益寿养生米肠及其加工方法 |
WO2008007728A1 (fr) | 2006-07-13 | 2008-01-17 | Kaneka Corporation | Préparation orale contenue dans une structure à membrane lipidique, et agent contre la fatigue comprenant une coenzyme comme ingrédient actif |
WO2008062559A1 (fr) | 2006-11-22 | 2008-05-29 | Asahi Kasei Pharma Corporation | Supplément diététique, agent anti-fatigue, activateur d'endurance physique, aliment fonctionnel, ou produit cosmétique |
JP2008136391A (ja) | 2006-11-30 | 2008-06-19 | Nisshin Pharma Inc | 若葉組成物 |
CA2680751C (en) | 2007-03-15 | 2016-01-26 | Suntory Holdings Limited | Use of dioxabicyclo[3.3.0]octane derivatives as anti-fatigue agents |
JP2008285463A (ja) | 2007-05-18 | 2008-11-27 | Makiko Funayama | 関節症・リウマチ・膠原病の治療薬 |
-
2007
- 2007-03-15 KR KR1020087025067A patent/KR101451438B1/ko active IP Right Grant
- 2007-03-15 AU AU2007237685A patent/AU2007237685B2/en not_active Ceased
- 2007-03-15 EP EP14184312.8A patent/EP2826481A1/de not_active Withdrawn
- 2007-03-15 SG SG201101846-2A patent/SG170120A1/en unknown
- 2007-03-15 MY MYPI20083572A patent/MY163134A/en unknown
- 2007-03-15 EP EP07738720.7A patent/EP1997496B1/de not_active Not-in-force
- 2007-03-15 JP JP2008510789A patent/JP5430927B2/ja active Active
- 2007-03-15 TW TW096109040A patent/TWI407963B/zh active
- 2007-03-15 US US12/282,707 patent/US20090054443A1/en not_active Abandoned
- 2007-03-15 CN CN2007800087982A patent/CN101410115B/zh active Active
- 2007-03-15 WO PCT/JP2007/055270 patent/WO2007119378A1/ja active Application Filing
- 2007-03-15 CA CA2645833A patent/CA2645833C/en active Active
-
2009
- 2009-06-18 HK HK09105474.5A patent/HK1126663A1/xx unknown
-
2013
- 2013-10-11 JP JP2013213305A patent/JP6095549B2/ja active Active
-
2014
- 2014-11-24 US US14/551,188 patent/US9895375B2/en active Active
-
2015
- 2015-03-10 HK HK15102411.0A patent/HK1201754A1/xx unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5180588A (en) * | 1989-07-21 | 1993-01-19 | Suntory Limited | Liver function improver |
US5211953A (en) * | 1989-07-21 | 1993-05-18 | Suntory, Limited | Liver function improver |
US5637610A (en) * | 1991-06-15 | 1997-06-10 | Suntory Limited | Composition containing dioxabicyclo [3.3.0] octane derivative |
US5814632A (en) * | 1991-09-13 | 1998-09-29 | Eisai Co., Ltd. | Immunopotentiating and infection protective agent and production thereof |
US5945420A (en) * | 1991-09-13 | 1999-08-31 | Eisai Co., Ltd. | Immunopotentiating and infection protective agent and production thereof |
US20040059110A1 (en) * | 2001-02-02 | 2004-03-25 | Ajinomoto Co., Inc. | Novel cystine derivative and agent for suppressing activation of inflammatory factors |
US20050158424A1 (en) * | 2002-04-11 | 2005-07-21 | Yuichiro Nakano | Liquid food/drink containing fat-soluble vitamin and method of stabilizing fat-soluble vitamin |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9895375B2 (en) | 2006-03-15 | 2018-02-20 | Suntory Holdings Limited | Compositions containing riboflavin and sesamin-class compounds |
US20100048695A1 (en) * | 2007-03-15 | 2010-02-25 | Yoshiko Ono | Anti-fatigue agent |
US9609884B2 (en) | 2007-03-15 | 2017-04-04 | Suntory Holdings Limited | Anti-fatigue agent |
US20100184793A1 (en) * | 2007-09-19 | 2010-07-22 | Suntory Holdings Limited | Compositions incorporating sesamin-class compounds and vitamin b1 class compounds |
US20100261785A1 (en) * | 2007-09-19 | 2010-10-14 | Suntory Holdings Limited | Compositions containing sesamin-class compound(s) and arachidonic acid class compound(s) |
US8653130B2 (en) | 2007-09-19 | 2014-02-18 | Suntory Holdings Limited | Compositions containing sesamin-class compound(s) and arachidonic acid class compound(s) |
US8703789B2 (en) | 2007-09-19 | 2014-04-22 | Suntory Holdings Limited | Compositions incorporating sesamin-class compounds and vitamin B1 class compounds |
US20210283165A1 (en) * | 2021-03-11 | 2021-09-16 | Nidal Toman | Constituent combination for treating stress |
Also Published As
Publication number | Publication date |
---|---|
MY163134A (en) | 2017-08-15 |
JP2014040463A (ja) | 2014-03-06 |
CA2645833A1 (en) | 2007-10-25 |
JPWO2007119378A1 (ja) | 2009-08-27 |
EP1997496A1 (de) | 2008-12-03 |
HK1126663A1 (en) | 2009-09-11 |
HK1201754A1 (en) | 2015-09-11 |
TW200803865A (en) | 2008-01-16 |
WO2007119378A1 (ja) | 2007-10-25 |
JP5430927B2 (ja) | 2014-03-05 |
AU2007237685A1 (en) | 2007-10-25 |
JP6095549B2 (ja) | 2017-03-15 |
US20150080407A1 (en) | 2015-03-19 |
KR101451438B1 (ko) | 2014-10-15 |
AU2007237685B2 (en) | 2012-08-09 |
US9895375B2 (en) | 2018-02-20 |
EP1997496A4 (de) | 2012-05-16 |
CN101410115B (zh) | 2012-01-04 |
CA2645833C (en) | 2014-12-30 |
SG170120A1 (en) | 2011-04-29 |
CN101410115A (zh) | 2009-04-15 |
EP2826481A1 (de) | 2015-01-21 |
EP1997496B1 (de) | 2015-07-29 |
KR20080110814A (ko) | 2008-12-19 |
TWI407963B (zh) | 2013-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9895375B2 (en) | Compositions containing riboflavin and sesamin-class compounds | |
EP2135606B1 (de) | Mittel gegen müdigkeit | |
US8703789B2 (en) | Compositions incorporating sesamin-class compounds and vitamin B1 class compounds | |
US20210353671A1 (en) | Compositions comprising cinnamaldehyde and zinc and methods of using such compositions | |
EP3169170B1 (de) | Zusammensetzung mit cinnamaldehyd und zink | |
JP5794761B2 (ja) | セサミン類及びビタミンeを含有する抗疲労剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SUNTORY LIMITED, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAKEMOTO, DAISUKE;TATEISHI, NORIFUMI;ONO, YOSHIKO;AND OTHERS;REEL/FRAME:021522/0521 Effective date: 20080905 |
|
AS | Assignment |
Owner name: SUNTORY HOLDINGS LIMITED, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SUNTORY LIMITED;REEL/FRAME:022653/0665 Effective date: 20090331 Owner name: SUNTORY HOLDINGS LIMITED,JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SUNTORY LIMITED;REEL/FRAME:022653/0665 Effective date: 20090331 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |